3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
3
Completed
3
Recruiting
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
3
Breast
3
Head & Neck
2
Dermatologic
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Melanoma
2
Recurrence
1
Neoplasms
1
Interventions
pembrolizumab
65
Nivolumab
58
Ipilimumab
32
Cyclophosphamide
22
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
cemiplimab
13
fludarabine
12
Opdualag
12
binimetinib
10
Blood Specimen Collection
10
aldesleukin
9
Radiosurgery
9
encorafenib
8
Interleukin-2
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Radiotherapy
5
Disulfides
5
Bevacizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Sodium Chloride
×
Dermatologic
×
Clear all
NCT05899465
2025-03-18
PRIME
University of Aarhus
Phase 3
Recruiting
1,204 enrolled
NCT04126876
2021-04-15
INTRIM
Amsterdam UMC, location VUmc
Phase 2
Recruiting
214 enrolled